Indian Journal of Medical Microbiology, published by Elsevier, is a pivotal peer-reviewed journal dedicated to the field of medical microbiology, providing a vital platform for research and scholarship since its inception in 1986. With an Open Access model established in 2001, it ensures the dissemination of scientific knowledge to a global audience, enhancing accessibility for researchers, professionals, and students alike. The journal's scope spans critical areas including immunology, infectious diseases, and microbiology, with an impressive trajectory marked by converged years of publication allowing for a comprehensive exploration of evolving scientific trends. As of 2023, the journal holds a Q3 ranking in Infectious Diseases and Microbiology (medical) and a Q4 ranking in Immunology and Microbiology categories, reflecting its significant yet growing impact in the field. Researchers seeking to contribute to or stay updated on the latest advancements in medical microbiology will find the Indian Journal of Medical Microbiology a valuable resource, as it consistently bridges the gap between emerging science and clinical application.

MIKROBIYOLOJI BULTENI, with ISSN 0374-9096, is a prestigious academic journal published by the ANKARA MICROBIOLOGY SOC, located in Ankara, Turkey. Established in 1973, this journal has been a vital conduit for disseminating research in the fields of Immunology, Microbiology, and Infectious Diseases, garnering a reputation as a significant contributor to the scientific community. The journal is currently ranked in the Q3 category within Immunology and Microbiology (miscellaneous), and Infectious Diseases, indicating its impactful presence amidst contemporary research. With access options that may be restricted, MIKROBIYOLOJI BULTENI actively welcomes submissions that advance the understanding of critical microbiological principles and practices, thereby supporting both national and international research efforts. Researchers, professionals, and students are encouraged to explore the latest findings shared in this journal, as it continually shapes the landscape of microbiology and infectious disease studies through its comprehensive and rigorous peer-reviewed publications.

Emerging Infectious Diseases, published by the Centers for Disease Control and Prevention, is a leading open-access journal that has been dedicated to the field of epidemiology, infectious diseases, and medical microbiology since its inception in 1995. With an impressive impact factor placing it in the Q1 quartile rankings for multiple categories including Epidemiology, Infectious Diseases, and Medical Microbiology, this journal serves as a vital resource for researchers, practitioners, and students dedicated to combating the challenges posed by emerging infectious diseases. The journal's distinguished Scopus ranks further highlight its global influence, ranking #10 in Epidemiology, #26 in Infectious Diseases, and #13 in Medical Microbiology, all within the top percentiles. Accessible and targeted, Emerging Infectious Diseases publishes seminal research and reviews that contribute to the understanding and management of infectious diseases, ensuring that critical insights reach a broad audience. The journal encourages contributions that advance the scientific community’s knowledge and responses to public health challenges.

Klimik Journal is a pivotal publication in the fields of Infectious Diseases and Medical Microbiology, serving as a platform for researchers, clinicians, and academics to disseminate groundbreaking findings and improve health outcomes. Established in 2010 and published by DOC DESIGN INFORMATICS CO LTD, this journal is dedicated to advancing knowledge and fostering discussions around critical issues in infectious diseases and microbial research. With an ISSN of 1301-143X and an E-ISSN of 1309-1484, Klimik Journal strives to maintain high academic standards despite currently ranking in the fourth quartile in both categories according to Scopus metrics, which highlights the need for continued contributions to the field. Operating from Turkey, the journal is committed to supporting open access options, thereby ensuring wide dissemination of research findings. As it continues to bridge the gap between theory and practice, Klimik Journal is poised to become an essential resource for those looking to stay at the forefront of infectious disease research and microbiological advancements.

Welcome to the Journal of Microbiology Immunology and Infection, a premier academic publication established in 1998 and now proudly owned by Elsevier Taiwan. As an Open Access journal since 2016, it provides unrestricted access to groundbreaking research in the fields of immunology, microbiology, and infectious diseases, making it an essential resource for researchers, practitioners, and students alike. The journal holds impressive rankings, including Q1 status in categories such as Infectious Diseases and Microbiology (medical), and a notable 92nd percentile in its Scopus ranking for Medicine - Infectious Diseases. With a dedicated focus on advancing knowledge and fostering collaboration within the scientific community, the Journal of Microbiology Immunology and Infection is committed to publishing high-impact research that significantly influences practice and policy in healthcare and life sciences. The journal is also recognized for its contribution to the ongoing dialogue surrounding contemporary issues in immunology and infection, positioning it as a vital platform for scholarly exchange and innovation.

Infectious Disease Reports is a premier open-access journal published by MDPI, dedicated to advancing the field of infectious diseases. Since its inception in 2009, this journal has established itself as a significant platform for disseminating cutting-edge research, reviews, and case studies, critical for global health. With a commendable Q2 ranking in the category of Infectious Diseases and a Scopus rank of #140 out of 344, it is recognized for its impactful contributions to medical research, holding a 59th percentile in its field. The journal aims to provide comprehensive insights into various dimensions of infectious diseases, ranging from epidemiology to novel treatment modalities. As an open-access publication, Infectious Disease Reports ensures that its articles are freely available to a wide audience, fostering collaborative efforts among researchers, healthcare professionals, and students worldwide. With its ongoing commitment to excellence, the journal plays an essential role in shaping the future of infectious disease research.

The Brazilian Journal of Infectious Diseases, published by Elsevier Brazil, is a premier open-access journal dedicated to advancing research and clinical practice in the field of infectious diseases. Since its inception in 2001, this journal has been pivotal in disseminating innovative studies and reviews that inform healthcare professionals and researchers alike. With an impressive impact factor reflected by its ranking in the second quartile for Infectious Diseases and third quartile for Medical Microbiology in 2023, the journal ranks #127 out of 344 in medicine – infectious diseases and #61 out of 140 in medical microbiology, showcasing its reputable standing in the scientific community. The Brazilian Journal of Infectious Diseases invites contributions that highlight significant findings, novel methodologies, and critical reviews aimed at enhancing patient care and public health initiatives. With an international readership and a focus on pressing issues in infectious diseases, it serves as an essential platform for knowledge exchange and collaboration among scholars and practitioners across Brazil and beyond. By reinforcing the importance of open access to scientific literature, this journal not only promotes transparency but also enhances the global discourse surrounding infectious diseases.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Infectious Microbes & Diseases, published by Lippincott Williams & Wilkins, is a premier journal dedicated to the exploration and understanding of infectious diseases, microbiology, and epidemiology. With its focused scope and robust peer-review process, the journal aims to disseminate high-quality research that contributes to advancements in the field, making it an essential resource for researchers, healthcare professionals, and students alike. Established in 2019, it has quickly gained recognition, achieving a Q3 rating in categories such as Epidemiology, Infectious Diseases, and Medical Microbiology in 2023, and ranking in the top half of its field within Scopus metrics. Although currently offered as a subscription-based journal, Infectious Microbes & Diseases significantly enriches its disciplines by inviting innovative research and critical review articles, thus playing a vital role in combating the global challenges posed by infectious diseases.

New Microbes and New Infections is an esteemed peer-reviewed journal published by Elsevier Sci Ltd that has been a prominent platform for disseminating groundbreaking research in the fields of Infectious Diseases and Microbiology since its establishment in 2013. With an impressive Open Access model, this journal ensures that vital research findings are readily accessible to researchers, healthcare professionals, and academics worldwide. Positioned in the Q2 category for Infectious Diseases and Q3 for Microbiology in 2023, it reaches a significant global audience, as demonstrated by its high Scopus rankings—#44 out of 344 in Medicine: Infectious Diseases, and #34 out of 182 in Immunology and Microbiology. The journal aims to inspire new ideas and foster collaborations by publishing high-quality research focused on novel microbes and infections, thus playing a crucial role in advancing science and public health in an era where understanding infectious agents is more vital than ever.